Literature DB >> 27297482

Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 5. Oseltamivir Carboxylate.

Danilo Cesar Galindo Bedor1, Sandrine Marchand2, Isabelle Lamarche3, Julian Laroche3, Davi Pereira de Santana4, William Couet5.   

Abstract

The aim of this study was to determine the biopharmaceutical characteristics of oseltamivir carboxylate (OC) after pulmonary delivery. After OC bolus and intratracheal nebulization (NEB) in rats, blood was collected and bronchoalveolar lavages (BALs) were performed. Epithelial lining fluid (ELF) concentrations were estimated from BAL fluid. The area under the curve (AUC) ratio for ELF to plasma was 842 times higher after NEB than after intravenous (i.v.) administration, indicating that OC nebulization offers a biopharmaceutical advantage over i.v. administration.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27297482      PMCID： PMC4958211          DOI： 10.1128/AAC.00909-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats.

Authors:  Sandrine Marchand; Patrice Gobin; Julien Brillault; Sara Baptista; Christophe Adier; Jean-Christophe Olivier; Olivier Mimoz; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 2.  Oseltamivir.

Authors:  A Bardsley-Elliot; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.

Authors:  Julien Brillault; Whocely Victor De Castro; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2009-10-12       Impact factor: 5.191

4.  Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam.

Authors:  Sandrine Marchand; Nicolas Grégoire; Julien Brillault; Isabelle Lamarche; Patrice Gobin; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin.

Authors:  Aline Vidal Lacerda Gontijo; Nicolas Grégoire; Isabelle Lamarche; Patrice Gobin; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

6.  Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.

Authors:  Deepak Gupta; Sheeba Varghese Gupta; Arik Dahan; Yasuhiro Tsume; John Hilfinger; Kyung-Dall Lee; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-01-04       Impact factor: 4.939

7.  P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.

Authors:  Julien Brillault; Whocely Victor De Castro; Thomas Harnois; Alain Kitzis; Jean-Christophe Olivier; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 8.  Influenza virus resistance to neuraminidase inhibitors.

Authors:  Mélanie Samson; Andrés Pizzorno; Yacine Abed; Guy Boivin
Journal:  Antiviral Res       Date:  2013-03-22       Impact factor: 5.970

9.  Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition.

Authors:  Zhe-Yi Hu; Andrea N Edginton; S Casey Laizure; Robert B Parker
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

10.  Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 3. Tobramycin.

Authors:  Sandrine Marchand; Nicolas Grégoire; Julien Brillault; Isabelle Lamarche; Patrice Gobin; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191
View more
  3 in total

1.  Pulmonary Pharmacokinetics of Oseltamivir Carboxylate in Rats after Nebulization or Intravenous Administration of Its Prodrug, Oseltamivir Phosphate.

Authors:  Romain Carrez; Julien Brillault; Nicolas Grégoire; Isabelle Lamarche; Julian Laroche; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Preclinical Pharmacokinetic and Pharmacodynamic Data To Support Cefoxitin Nebulization for the Treatment of Mycobacterium abscessus.

Authors:  Shachi Mehta; Vincent Aranzana-Climent; Blandine Rammaert; Nicolas Grégoire; Sandrine Marchand; William Couet; Julien M Buyck
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 3.  The pulmonary route as a way to drug repositioning in COVID-19 therapy.

Authors:  Michelle Alvares Sarcinelli; Thalita Martins da Silva; Andressa Daniele Artico Silva; Beatriz Ferreira de Carvalho Patricio; Flávia Costa Mendes de Paiva; Raissa Santos de Lima; Manuela Leal da Silva; Helvécio Vinícius Antunes Rocha
Journal:  J Drug Deliv Sci Technol       Date:  2021-02-24       Impact factor: 5.062
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.